Shares in C4X Discovery Holdings PLC have rocketed after the company licensed a potential best-in-class addiction candidate to fellow UK firm Indivior PLC in a deal that could be worth up to $294m.
The pact, for which C4XD is getting $10m up front and a further $284m of potential development, regulatory and commercialization...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
